A study commissioned by three of the UK’s leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research.

In a time of uncertainty, venture capitalists are shifting from biotech to the lower-risk, lower-reward field of MedTech.

Cancer Research UK (CRUK) launched a five-year plan which will see the charity spend around GBP 300 million a year on core areas of science in a bid to reduce cancer deaths, including greater investment in cancers where survival rates are poor.

US genomics firm Myriad Genetics regains limited rights to BRCA1 breast cancer gene on final appeal.

Whether someone will become an entrepreneur may be down to whether they make risky decisions. And for those without this innate ability, teaching or drugs could help enhance entrepreneurial skills.